Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23015244 | 1.00 | ACP1 (0.63) | ACP1SLC2A1 | |
| Hydrochloric Acid SCHEMBL29636768 | 0.99 | ACP1 (0.62) | ACP1SLC2A1 | |
| SCHEMBL29636787 | 0.98 | ACP1 (0.66) | ACP1SLC2A1 | |
| SCHEMBL23015094 | 0.98 | ACP1 (0.66) | ACP1SLC2A1 | |
| SCHEMBL23029722 | 0.90 | ACP1 (0.63) | ACP1SLC2A1 | |
| SCHEMBL23029674 | 0.90 | ACP1 (0.66) | ACP1SLC2A1 | |
| SCHEMBL29636786 | 0.90 | ACP1 (0.73) | ACP1SLC2A1 | |
| SCHEMBL23029664 | 0.90 | ACP1 (0.73) | ACP1SLC2A1 | |
| SCHEMBL23029619 | 0.89 | ACP1 (0.64) | ACP1SLC2A1 | |
| Hydrochloric Acid SCHEMBL23015218 | 0.89 | ACP1 (0.72) | ACP1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388962-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 2022-12-08 | — | — | US | claimed |
| EP-4017492-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | Biohaven Therapeutics Ltd. (US) | 2022-06-29 | — | — | EP | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388962-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | TARDBP, TDP1, TDP2 | ACP1 1840/4885SLC2A1 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.